Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (321-330 of 713) with videos related to

Pageof 72
Sort By:
Blood|February 22, 2003
Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndromeJorge Cortes, Patricia Ault, Charles Koller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemiaHagop M Kantarjian, Moshe Talpaz, Jorge Cortes, et al.
Leukemia Research|July 16, 2003
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemiaApostolia Tsimberidou, Jorge Cortes, Deborah Thomas, et al.
Leukemia Research|June 27, 2006
Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kitSrdan Verstovsek, Cem Akin, Taghi Manshouri, et al.
Cancer|January 2, 2009
Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phaseHagop M Kantarjian, Richard A Larson, Francois Guilhot, et al.
Cancers|January 11, 2025
Caught in the Crossfire: Unmasking the Silent Renal Threats of Tyrosine Kinase Inhibitors in Chronic Myeloid LeukemiaMaria Benkhadra, Rola Ghasoub, Reem Hajeomar, et al.
Blood|July 13, 2007
Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phaseElias Jabbour, Hagop M Kantarjian, Lynne V Abruzzo, et al.
Cancer|August 26, 2010
Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission durationHagop M Kantarjian, Deborah Thomas, Farhad Ravandi, et al.
Cancer|September 17, 2010
Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemiaAref Al-Kali, Hagop Kantarjian, Jianqin Shan, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 25, 2013
Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabineElias Jabbour, Hagop Kantarjian, Susan O'Brien, et al.
Pageof 72

Showing results (321-330 of 713) with videos related to

Sort By:
Pageof 72
Blood|February 22, 2003
Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndromeJorge Cortes, Patricia Ault, Charles Koller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemiaHagop M Kantarjian, Moshe Talpaz, Jorge Cortes, et al.
Leukemia Research|July 16, 2003
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemiaApostolia Tsimberidou, Jorge Cortes, Deborah Thomas, et al.
Leukemia Research|June 27, 2006
Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kitSrdan Verstovsek, Cem Akin, Taghi Manshouri, et al.
Cancer|January 2, 2009
Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phaseHagop M Kantarjian, Richard A Larson, Francois Guilhot, et al.
Cancers|January 11, 2025
Caught in the Crossfire: Unmasking the Silent Renal Threats of Tyrosine Kinase Inhibitors in Chronic Myeloid LeukemiaMaria Benkhadra, Rola Ghasoub, Reem Hajeomar, et al.
Blood|July 13, 2007
Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phaseElias Jabbour, Hagop M Kantarjian, Lynne V Abruzzo, et al.
Cancer|August 26, 2010
Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission durationHagop M Kantarjian, Deborah Thomas, Farhad Ravandi, et al.
Cancer|September 17, 2010
Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemiaAref Al-Kali, Hagop Kantarjian, Jianqin Shan, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 25, 2013
Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabineElias Jabbour, Hagop Kantarjian, Susan O'Brien, et al.
Pageof 72